Press Release

October 16, 2026 The Manager – Listing BSE Limited P J Towers, Dalal Street, Fort, Mumbai 400001 The Manager – Listing National Stock Exchange of India Ltd. Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai 400051 Dear Sirs/ Madam, Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Press Release Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed a copy of the press release titled “AstraZeneca Pharma India announces new Mumbai Corporate Office, marking the next phase of growth through innovation" being issued by the Company. Kindly take the above information on record. Thanking you, For AstraZeneca Pharma India Limited Tanya Sanish Company Secretary & Compliance Officer ACS No.: A25784 Encl: As above Press Release AstraZeneca Pharma India announces new Mumbai corporate office, marking the next phase of growth through innovation Mumbai, 16 October 2026: AstraZeneca Pharma India Limited today inaugurated its new corporate office in Mumbai, marking an extension of company’s presence in India, reinforcing its ambition to transforming care by unlocking the power of science. The new office spread across 25,600 sq ft was inaugurated today by Honorable Shri Devendra Fadnavis, Chief Minister of Maharashtra alongside senior government officials, dignitaries from embassies and AstraZeneca team. AstraZeneca has introduced more than 25 new medicines and indications in India over the past three years and is currently running about 80 global clinical trials in the country, supporting the development of new treatments, strengthening India’s contribution to global research and getting the right medicines to the right patients, faster. Shri Devendra Fadnavis, Hon’ble Chief Minister of Maharashtra, said “Maharashtra has a strong and growing pharmaceutical and life sciences ecosystem, supported by skilled talent, leading institutions and robust healthcare infrastructure. AstraZeneca’s decision to establish its India commercial office in Mumbai reflects confidence in the state’s capabilities and its potential as an innovation hub. We welcome AstraZeneca’s continued commitment to Maharashtra and look forward to the opportunities this will create for collaboration, capability building and skilled employment.” “India is at an important inflection point in healthcare, with a growing need for earlier diagnosis, innovative treatments and more equitable access,” said Praveen Rao Akkinepally, Country President and Managing Director, AstraZeneca Pharma India Limited. “Our stronger presence in Mumbai strengthens our ability to work with partners across the healthcare ecosystem and advance solutions that address the needs of patients in India. Our strong workforce of nearly 5,000 colleagues across the country are united by a common ambition to follow the science, advance access to life saving therapies and help more people live better, healthier lives.” At the center of its ambition is the organization’s unwavering focus on pioneering newer access pathways so life-saving therapies can reach every patient that needs them. Working closely with governments and industry, AstraZeneca has focused on leveraging AI and building solutions across the continuum of care – from prevention, awareness, to diagnosis and treatment, at scale. This strategic move presents several opportunities to the organization for a closer and effective partnership with a vibrant and fast-evolving healthcare ecosystem across therapy areas it is present in-Oncology, Biopharmaceuticals and Rare Disease. Arun Krishna, Non-Executive Director on the Board of AstraZeneca Pharma India Limited and Area Vice President, Asia, AstraZeneca, said “India is an increasingly important contributor to AstraZeneca’s growth across Asia. The momentum of our business, the evolution of our portfolio, and the depth of talent and capabilities in the country provides a strong foundation for the opportunity ahead. Our new commercial office in Mumbai will support closer engagement with stakeholders and the continued development of our people, strengthening India’s contribution to our regional and global ambition.” This step will also support AstraZeneca’s continued investment in talent and capability building in India, creating opportunities for professionals who are passionate about transforming healthcare through science, technology and collaboration. As the company expands, it will seek to attract and develop diverse talent across the value chain. Establishing a stronger footprint in Mumbai is a part of AstraZeneca’s broader purpose of advancing equitable healthcare globally. With this, India becomes one of the largest and diverse footprints of the organization around the world that supports commercial operations, site management and monitoring, technology, research and development, and global business services. With the opening of this Mumbai office, AstraZeneca in India is entering its next phase of growth one focused on expanding access to innovation, deepening partnerships and helping address the country’s most pressing healthcare needs. About AstraZeneca India AstraZeneca is a global science-led biopharmaceutical company, it focuses on the discovery, development and commercialisation of prescription medicines across key therapy areas including Oncology, Biopharmaceuticals and Rare Disease. With a workforce of over 5000 employees across the country, the organisation is committed to advancing innovative science, expanding access to differentiated medicines and contributing meaningfully to patient care through strong commercial execution and partnerships across the healthcare ecosystem. For media queries, please contact: Pooja Behuria: pooja.behuria@astrazeneca.com Gunjan Gupta: gunjan.gupta@astrazeneca.com